HOW IS OLEPTRO DOING??

Quote
Make sure you use your bonus money to buy all the Labopharm stock you can...oh wait, I forgot they don't pay a bonus.

"Co also announced that the board of directors of the Corporation in conjunction with its management have undertaken a complete review of the business including consideration of all available strategic options."

Changes are coming...
 


















Anonymous said:
"Co also announced that the board of directors of the Corporation in conjunction with its management have undertaken a complete review of the business including consideration of all available strategic options."
Click to expand...

That crazy talk. Pure crazy talk. "Strategic options" would be viable if they were developed by people who know what they're doing in this market. In this organization, if you don't have any knowledge or successful experience managing complex and large projects, you're in management. Sorry investors - the people who sank the boat are telling you it's going to get better.
 












Anonymous said:
That crazy talk. Pure crazy talk. "Strategic options" would be viable if they were developed by people who know what they're doing in this market. In this organization, if you don't have any knowledge or successful experience managing complex and large projects, you're in management. Sorry investors - the people who sank the boat are telling you it's going to get better.
Click to expand...

Strategic options means it's for sale. The whole thing, not just Oleptro. Best way to find out what a company is really worth. Sell it.
 






Anonymous said:
And when you thought that things couldn't get worse, the CFO is moved up to be the President. Put someone who knows modern medicine (by education and training...) in charge and put the bean-counters back into the basement where they belong.
Click to expand...

I do not understand why everyone is so hyped up about what happens to Labopharm. This project is with Angelini Labipharm which is a joint venture. If Labopharm is sold (which certainly seems likely with the CFO now in charge), that can only be a good thing for the JV team - especially if it is sold to Anglini.
 






Anonymous said:
I do not understand why everyone is so hyped up about what happens to Labopharm. This project is with Angelini Labipharm which is a joint venture. If Labopharm is sold (which certainly seems likely with the CFO now in charge), that can only be a good thing for the JV team - especially if it is sold to Anglini.
Click to expand...

Selling to Angelini will in no way increase Oleptro's market potential or market performance. The product cannot and will not establish a comparative advantage versus other available drugs used in the treatment of depression which would make it more readily prescribed. It's market performance to-date is the function of that reality.
 






Anonymous said:
Selling to Angelini will in no way increase Oleptro's market potential or market performance. The product cannot and will not establish a comparative advantage versus other available drugs used in the treatment of depression which would make it more readily prescribed. It's market performance to-date is the function of that reality.
Click to expand...

There are definitely clinical advantages but there are over riding market forces-large number of viable generic options at low cost-that we are not able to overcome. The AD market has changed significantly, especially because of citalopram and now Lexapro soon to go generic. The best insight into whether the market can revert back is when Vibriid is launched, can a large, previously very successful, company like Forest make a huge brand name dent in the generic stranglehold of anti-depressants.
 






Anonymous said:
There are definitely clinical advantages
Click to expand...

Wrong. If there were evidence-based-medicine methodologies demonstrating significant clinical advantages of Oleptro, the presence of generics in the marketplace would make no difference. Medicine and the marketplace know about Oleptro while the people who market it do not.
 






Anonymous said:
Wrong. If there were evidence-based-medicine methodologies demonstrating significant clinical advantages of Oleptro, the presence of generics in the marketplace would make no difference. Medicine and the marketplace know about Oleptro while the people who market it do not.
Click to expand...

There is significant EBM in the literature, the challenges are having a small voice and a significantly different marketplace than was believed to exist.
 






Anonymous said:
There is significant EBM in the literature, the challenges are having a small voice and a significantly different marketplace than was believed to exist.
Click to expand...

There is not significant EBM for Oleptro. For example, only one citation in the PubMed database and it references approval, nothing else. There is not a single Grade One study in the remaining databases.
 






What is the message coming from management about this project? Is there a serious threat that the contract will be broken or is this gossip. Have an interview with this contract and am trying to read the truth from the bs posted here.
 






Anonymous said:
What is the message coming from management about this project? Is there a serious threat that the contract will be broken or is this gossip. Have an interview with this contract and am trying to read the truth from the bs posted here.
Click to expand...

Although the product isn't doing very well, it would seem the contract is stable via it being a joint venture between Angelini and Labopharm. I think it's probable that after July and before Christmas they will "buy out" the contract and hire reps directly. If they do that, it would be a big unknown as to whether they keep territories exactly the same, add or subtract. Would they roll everyone over? Unknown since there aren't any territories meeting the original goals set by Angelini/Labo.
 






Anonymous said:
Although the product isn't doing very well, it would seem the contract is stable via it being a joint venture between Angelini and Labopharm. I think it's probable that after July and before Christmas they will "buy out" the contract and hire reps directly. If they do that, it would be a big unknown as to whether they keep territories exactly the same, add or subtract. Would they roll everyone over? Unknown since there aren't any territories meeting the original goals set by Angelini/Labo.
Click to expand...

Thank you for your response.
 






first the JV needs to get rid of the failed heinnie!!!!! then it needs to bring in some strong marketing talent!! it will be very hard to save a failed product that has been on the market this long, the market has already decided it doed not want the product
 






Anonymous said:
Although the product isn't doing very well, it would seem the contract is stable via it being a joint venture between Angelini and Labopharm. I think it's probable that after July and before Christmas they will "buy out" the contract and hire reps directly. If they do that, it would be a big unknown as to whether they keep territories exactly the same, add or subtract. Would they roll everyone over? Unknown since there aren't any territories meeting the original goals set by Angelini/Labo.
Click to expand...
There's no reason to do any of that. Why? Because the original business model and the assumptions that created it have not changed. Buying people out, rolling people over does not alter the performance of the drug in the marketplace. Oleptro had a chance 26 years ago, in today's market: zero.
 






Close it down. Now. Only two representatives are needed for this product. One to work with the third-party payors, the other to work with the wholesalers. Anything beyond that is a waste of money.
 


















Top Bottom
Back
Quote